ClinicalTrials.gg
CompletedNCT07028320Updated Jun 25, 2025

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

A Phase 3 interventional study of SAL056 (56.5μg) and Alendronate in Postmenopausal Women With Osteoporosis, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to female participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Dec 2021, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Enrollment
7th of 57
493 · median 120
Started
2021
with 8 others
Phase 3
11 of 87
3 open now
Registered
71st of 87
by date
Lead sponsor
3 of 87
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 87 studies in Osteoporosis with a site in China, this one is the 7th largest by enrollment of the 57 interventional ones that give a count, is one of 9 that started in 2021, is one of 11 in phase 3, and was the 71st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk

Read the detailed description

The trial consists of a screening period (4 weeks), an open-label treatment period (up to 48 weeks), and a follow-up period (1 weeks), totaling approximately 53 weeks. Subjects who withdraw early will be asked to complete an end of treatment visit, and a safety follow-up visit 2 weeks after the end of treatment visit.

03

Conditions studied

  • Postmenopausal Women With Osteoporosis

Browse trials for

Keywords

  • Postmenopausal Women With Osteoporosis; Teriparatide
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women with the ability to live independently (≥45 and ≤80 years);
  2. The patient has a (BMI) of 18.0 kg/m2 to 30 kg/m2; The patient has one of the following diagnostic criteria for osteoporosis and subject has at least 2 consecutive vertebrae region (L1 to L4) that are evaluable by dual-energy x-ray absorptiometry (DXA),a) History of hip/vertebra fragility fracture and bone mineral density (BMD) T-score ≤-1; b)the axial bone (lumbar , femoral neck or total hip) mineral density (BMD) T-score ≤-2.50;c) Bone mineral density (BMD) T-score ≥-2.5 and ≤-1 with proximal humerus, pelvis, or distal forearm end fragility fracture

Exclusion criteria

Exclusion Criteria:

  1. In addition to osteoporosis, the other diseases affecting bone metabolism;
  2. Patients with other diseases affecting calcium or bone metabolism;
  3. Received anti-osteoporosis treatment that does not meet protocol requirements;
  4. Received medication that affects bone metabolism prior to screening, or is planned to use prohibited drugs/non-drug therapy under the protocol during the study period;
  5. Patients requiring long-term or continuous use of digoxin and other digitalis drugs during the trial;
  6. Patients with other severe underlying diseases; Patients with abnormal indicators that does not meet protocol requirements during the screening periodlaboratory tests
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    Drug: SAL056 (56.5μg)

    Administered by subcutaneous injection once a week during treatment phase

    Drug: SAL056 (56.5μg)

  • Active comparator
    Drug: Alendronate

    70 mg tablet taken once a week during treatment phase

    Drug: Alendronate

Interventions

  • DrugSAL056 (56.5μg)

    Administered by subcutaneous injection once a week during treatment phase

    Also known as: Teriparatide for Injection

  • 70 mg tablet taken once a week during treatment phase

06

What researchers measure

Primary outcomes

  1. Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 48 Weeks

    Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 48 Weeks

    Time frame: Baseline to 48 Weeks

Secondary outcomes

  1. Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 24 Weeks

    Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 24 Weeks

    Time frame: Baseline to 24 Weeks

  2. Percent Change in Bone Mineral Density (BMD) of Total Hip from Baseline to 24/48 Weeks

    Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to 24/48 Weeks

    Time frame: Baseline to 24/48 Weeks

  3. Percent Change in S-CTX and P1NP From Baseline to12/ 24/48 Weeks

    Percent Change in S-CTX and P1NP From Baseline to 12/24/48 Weeks

    Time frame: Baseline to 12/24/48 Weeks

  4. Proportion of Subjects with New Fragility Fractures from Baseline to 24/48 Week

    Proportion of Subjects With New Fragility Fractures from Baseline to 24/48 Weeks

    Time frame: Baseline to 24/48 Weeks

07

Study locations

1 site
  • Shanghai Sixth People's Hosptital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Dec 2023, 24 months.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 24 months is close to that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartActual
Dec 3, 2021
Primary completionActual
Dec 30, 2023
CompletionActual
May 20, 2024
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07028320
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Dec 3, 2021
Primary completion
Dec 30, 2023
Completion
May 20, 2024
Last update
Jun 25, 2025

Study contacts

Zheng Lin Zhang
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion